Fifty years of monoclonals: the past, present and future of antibody therapeutics

2025/08/07 by Andrew C. Chan, Gregory D. Martyn, Greg D. Martyn +1 · 1 voice · 1 citation
Medicine · #CAR-T cell therapy research #HER2/EGFR in Cancer Research #Monoclonal and Polyclonal Antibodies Research

paper · doi:10.1038/s41577-025-01207-9

crossref issued 2025/08/07 · crossref published 2025/08/07 · crossref published-online 2025/08/07 · openalex publication_date 2025/08/07 · crossref created 2025/08/07 · crossref published-print 2025/10/01 · openalex created_date 2025/10/10 · crossref deposited 2025/12/15 · crossref indexed 2026/07/31 · openalex updated_date 2026/08/02

Citations

• Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
• Highly accurate protein structure prediction with AlphaFold
• Atomically accurate de novo design of antibodies with RFdiffusion
• Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
• New Multiple Sclerosis Phenotypic Classification
• Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

Cited by

• Nanobodies: A Promising Toolkit for Diagnostic Applications

Discussions

• Chan, A.C., et al. Fifty years of monoclonals: the past, present and future of antibody therapeutics. Nat Rev Immunol (2025). doi.org/10.1038/s415... [bsky, 1 points, 0 comments]